Multiple Sclerosis Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, unpredictable disease that leads to the loss of information exchange in the brain and between the brain and body. MS affects the central nervous system principally spinal cord, optic nerves, and the brain. In Multiple Sclerosis, damaging of insulating covers of nerve cells by demyelinating of these covers in the brain and spinal cord.

In MS, symptoms are like numbness, tingling, dizziness and fatigue, sexual dysfunction, muscle weakness, ataxia, acute or chronic pain, change in sensation, vision problems, tremor, memory problems, and muscle spasms. Signs and symptoms may vary in MS and it depends on the level of the damage to nerve cells.

Multiple Sclerosis is an autoimmune disorder, in which the immune system attacks the myelin sheath which protects the nerve cells leads to communication problems in the body. The main cause behind this is not yet found. But it is believed that it is a result of accumulated genetic and environmental factors. Some cause may be genetic, geographical, infection, and acquired factors as well.

Multiple Sclerosis has no cure. Medication helps to prevent new attacks or to stabilize functioning after an attack.

Sub-tracks:

Primary progressive MS
Relapse-remitting MS (RRMS)
Secondary progressive MS (SPMS)
Clinically isolated syndrome (CIS)
Multiple Sclerosis Treatment and Management
Multiple Sclerosis case reports

Market Analysis: The global market for multiple sclerosis (MS) medicines was worth $22.99 billion in 2018, and is expected to reach $28.00 billion by 2026, with a CAGR of 2.5 percent between 2019 and 2026. Multiple sclerosis is a chronic inflammatory disease that causes demyelination, axonal transection, and neurodegeneration in the brain and spinal cord's nerve cells. The global market for multiple sclerosis medications is valued at $27.38 billion in 2021 and is predicted to grow at a CAGR of 6.3 percent to $41.99 billion in 2028. MS affects around 57.8 people per 100,000 in the United States. The prevalence is stated to be 68.8 per 100,000 above the 37th parallel and 35.5 per 100,000 below it. Scientists are still working hard to develop new and improved treatments for MS. By 2028, the global market for multiple sclerosis drugs will be valued $ 42.46 billion, with a 6.3 percent compound annual growth rate.

Tracks